Provided by Tiger Trade Technology Pte. Ltd.

Core Assets of Southward Funds

1,014.313
-8.298-0.81%
Number of Gainers:12
Number of Losers:54
Number of Flat:1
PE:- -
High:1,022.907
Open:1,021.070
Low:1,012.159
Close:1,022.611
Volume:777.59M
Turnover:20.58B
Market Cap:13.79T
Float Cap:12.83T

Loading ...

Nongfu Spring H1 Revenue RMB 29,718 Million

THOMSON REUTERS
·
Aug 25

Yadea's First-Half Profit Dips 27% as E-Bike Price Wars Bite Into Margins

Deep News
·
Aug 25

Innovent Biologics' H1 Profit Jumps 50%

MT Newswires Live
·
Aug 25

Shenzhou International Says it is Accelerating Integration of Digitalisation, Smart Manufacturing Others

Reuters
·
Aug 25

Haidilao International Holding Declares Interim Dividend Hkd0.377 Per Share

Reuters
·
Aug 25

Haidilao FY26 H1 Profit Rises 0.5% to RMB 1.76 Billion; Revenue Increases 7.9% to RMB 22.34 Billion

Reuters
·
Aug 25

Haidilao International Holding - Declare an Interim Dividend of Hkd0.377 Per Share

THOMSON REUTERS
·
Aug 25

Haidilao International Holding H1 Net Income Attributable RMB 1,766.9 Million

THOMSON REUTERS
·
Aug 25

Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026

THOMSON REUTERS
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25

Innovent Announces 2026 Interim Results and Business Updates

THOMSON REUTERS
·
Aug 25

INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year

Stock News
·
Aug 25

China's Former Richest Man Donates Nearly 1 Billion Yuan in Shares to Charity

Deep News
·
Aug 25

Southbound Capital Flow Update: Net Selling Reaches HK$6.605 Billion, Funds Rotate Into AI Model Stocks While Exiting Laminate Maker

Stock News
·
Aug 25

Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030

THOMSON REUTERS
·
Aug 25

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

Innovent Biologics H1 Revenue RMB 8,617.8 Million

THOMSON REUTERS
·
Aug 25

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Aug 25